Influence of Physiological Variables and Comorbidities on Plasma Aβ40, Aβ42, and p-tau181 Levels in Cognitively Unimpaired Individuals.

Alzheimer’s disease amyloid comorbidities plasma biomarkers presymptomatic stages tau protein

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
25 Jan 2024
Historique:
received: 24 12 2023
revised: 20 01 2024
accepted: 23 01 2024
medline: 10 2 2024
pubmed: 10 2 2024
entrez: 10 2 2024
Statut: epublish

Résumé

Plasma biomarkers for Alzheimer's disease (AD) are a promising tool that may help in early diagnosis. However, their levels may be influenced by physiological parameters and comorbidities that should be considered before they can be used at the population level. For this purpose, we assessed the influences of different comorbidities on AD plasma markers in 208 cognitively unimpaired subjects. We analyzed both plasma and cerebrospinal fluid levels of Aβ40, Aβ42, and p-tau181 using the fully automated Lumipulse platform. The relationships between the different plasma markers and physiological variables were studied using linear regression models. The mean differences in plasma markers according to comorbidity groups were also studied. The glomerular filtration rate showed an influence on plasma Aβ40 and Aβ42 levels but not on the Aβ42/Aβ40 ratio. The amyloid ratio was significantly lower in diabetic and hypertensive subjects, and the mean p-tau181 levels were higher in hypertensive subjects. The glomerular filtration rate may have an inverse relationship on plasma Aβ40 and Aβ42 levels but not on the amyloid ratio, suggesting that the latter is a more stable marker to use in the general population. Cardiovascular risk factors might have a long-term effect on the amyloid ratio and plasma levels of p-tau181.

Identifiants

pubmed: 38338759
pii: ijms25031481
doi: 10.3390/ijms25031481
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Francisco Martínez-Dubarbie (F)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.

Armando Guerra-Ruiz (A)

Biochemistry and Clinical Analysis Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.

Sara López-García (S)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.

Juan Irure-Ventura (J)

Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
Immunology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.

Carmen Lage (C)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
Atlantic Fellow for Equity in Brain Health, Global Brain Health Institute, University of California, San Francisco, CA 94143, USA.

Marta Fernández-Matarrubia (M)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.

Ana Pozueta-Cantudo (A)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.

María García-Martínez (M)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.

Andrea Corrales-Pardo (A)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
Health Sciences Department, Universidad Europea del Atlántico, 39011 Santander, Spain.

María Bravo (M)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.

Juan Martín-Arroyo (J)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.

Jon Infante (J)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28220 Madrid, Spain.
Medicine and Psychiatry Department, University of Cantabria, 39011 Santander, Spain.

Marcos López-Hoyos (M)

Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
Immunology Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Molecular Biology Department, University of Cantabria, 39011 Santander, Spain.

María Teresa García-Unzueta (MT)

Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
Biochemistry and Clinical Analysis Department, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.

Pascual Sánchez-Juan (P)

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28220 Madrid, Spain.
CIEN Foundation, Queen Sofia Foundation Alzheimer Center, 28220 Madrid, Spain.

Eloy Rodríguez-Rodríguez (E)

Neurology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Institute for Research Marqués de Valdecilla (IDIVAL), 39011 Santander, Spain.
Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28220 Madrid, Spain.
Medicine and Psychiatry Department, University of Cantabria, 39011 Santander, Spain.

Classifications MeSH